William Demant CEO: Opn is in absolute top form

After more than a year on the market, the essential top-line product of William Demant, the hearing device Oticon Opn, is still the group’s major asset and the main source of continuing growth. This is according to the CEO of Denmark’s biggest hearing aids group. He also predicts a bright future for the bone conduction business Oticon Medical.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

MSD's Keytruda fejler i mavekræftstudie

Immunterapien Keytruda fra amerikanske Merck/MSD har ikke kunnet overgå kemoterapi i andenlinjebehandling af patienter med kræft i mave eller spiserør. Lægemidlet blev for få måneder siden godkendt i indikationen i tredje linje.

Latest Top picks in English

Related articles